ШУЛЕР Вальтер (DE),ШТЕГМАЙЕР Франк П. (US),ВАРМУТ Маркус (US)
申请号：
RU2012146083/15
公开号：
RU2012146083A
申请日:
2011.03.28
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. Use of a PKC inhibitor as a medicament for the treatment of B-cell lymphoma possessing a chronically active signaling cascade of the B-cell receptor. The use according to claim 1, wherein said B-cell lymphoma is a CD79 mutant diffuse B-large cell lymphoma. The use according to claim 2, wherein said B-cell lymphoma is non-Hodgkins lymphoma. The use according to claims 1, 2 or 3, wherein said PKC inhibitor is a selective inhibitor of PKCa / b. The use according to claims 1, 2 or 3, wherein said PKC inhibitor is selected from the group consisting of sotrastaurin 3- (1-indol-3-yl) -4- [2- (piperazin-1-yl) quinazolin-4-yl ] -1-pyrrole-2,5-dione 3- [2-chloro-7 - [(dimethylamino) methyl] -1-naphthalenyl] -4- [7- [2- {2-methoxyethoxy) ethoxy] -1H -indol-3-yl] -1H-pyrrole-2,5-dione 3- [3- (4,7-diaza-spiro [2, 5] oct-7-yl) isoquinolin-1-yl] -4- (7-methyl-1H-indol-3-yl) pyrrole-2,5-dione 3- [2-chloro-7 - [(dimethylamino ) methyl] -1-naphthalenyl] -4- [7- [2- (2-methoxyethoxy) ethoxy] -1H-indol-3-yl] -1H-pyrrole-2,5-dione and (9S) -9 - [(dimethylamino) methyl] -6,7,10,11-tetrahydro-9H, 18H-5.21: 12,17-dimethenodibenzo [e, k] pyrrolo [3,4-h] [1,4,13] oxadiazacyclohexadecin-18.20 (19H) -dione, or a pharmaceutically acceptable salt thereof. The use according to claim 5, wherein said PKC inhibitor is co-taraurin. Use of a PKC inhibitor and at least one additional pharmaceutical agent that is an mTOR inhibitor, a PI3K inhibitor or a JAK inhibitor as a medicine for treating B-cell lymphoma having a chronic active B-cell receptor signaling cascade. The use according to claim 7, wherein said B-cell lymphoma is a CD79 mutant diffuse B-large cell lymphoma. The use according to claim 8, wherein said B-cell limus1. Применение ингибитора PKC в качестве лекарственного средства для лечения B-клеточной лимфомы, обладающей хронически активным сигнальным каскадом B-клеточного рецептора.2. Применение по п.1, где указанная B-клеточная лимфома представляет собой мутантную по CD79 диффузную B-кру
